Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzyvant Therapeutics, Inc.

http://www.enzyvant.com

Latest From Enzyvant Therapeutics, Inc.

Mallinckrodt StrataGraft Skin Therapy Could Be The First RMAT-Designated Therapy Approved By US FDA

The company presented positive data from a Phase III pivotal trial during the American Burn Association virtual annual meeting.

Regenerative Medicine Clinical Trials

Dainippon Lays Out R&D Table Ahead Of Latuda Challenges

Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.

Clinical Trials Innovation

Start-Up Quarterly Statistics: Financings Surged In Q4 While M&A Waned

A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.

Deals Financing

Deal Watch: Conatus Ends NASH Ambitions, Merges With Regenerative Medicine Firm Histogen

Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Enzyvant Sciences, Ltd.
UsernamePublicRestriction

Register